{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:21:57Z","timestamp":1787772117871,"version":"build-2784847793"},"reference-count":136,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Neuro-ophthalmologic diseases include a broad range of disorders affecting the afferent and efferent visual pathways. Recently, monoclonal antibody (mAb) therapies have emerged as a promising targeted approach in the management of several of these complex conditions. Here, we describe the mechanism-specific applications and advancements in neuro-ophthalmologic mAb therapies. The application of mAbs in neuro-ophthalmologic diseases highlights our increasing understanding of disease-specific mechanisms in autoimmune conditions such as neuromyelitis optica, thyroid eye disease, and myasthenia gravis. Due to the specificity of mAb therapies, applications in neuro-ophthalmologic diseases have yielded exceptional clinical outcomes, including both reduced rate of relapse and progression to disability, visual function preservation, and quality of life improvement. These advancements have not only expanded the range of treatable neuro-ophthalmologic diseases but also reduced adverse events and increased the response rate to treatment. Further research into neuro-ophthalmologic disease mechanisms will provide accurate and specific targeting of important disease mediators through applications of future mAbs. As our understanding of these diseases and the relevant therapeutic targets evolve, we will continue to build on our understanding of how mAbs interfere with disease pathogenesis, and how these changes improve clinical outcomes and quality of life for patients.<\/jats:p>","DOI":"10.4103\/sjopt.sjopt_256_23","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T13:00:37Z","timestamp":1711717237000},"page":"13-24","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Monoclonal antibodies in neuro-ophthalmology"],"prefix":"10.4103","volume":"38","author":[{"given":"Caroline C.","family":"Keehn","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Yazdian","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Davila-Siliezar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor A.","family":"Laylani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, USA"},{"name":"Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, USA"},{"name":"Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, USA"},{"name":"Departments of Ophthalmology, Neurology, and Neurosurgery, Weill Cornell Medicine, New York, USA"},{"name":"Department of Ophthalmology, University of Texas Medical Branch, Galveston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10620-017-4478-1","article-title":"Development of monoclonal antibodies:The dawn of mAb rule","volume":"62","author":"Kaunitz","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/eji.1830060713","article-title":"Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion","volume":"6","author":"K\u00f6hler","year":"1976","journal-title":"Eur J Immunol"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics:History and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1080\/21645515.2015.1074362","article-title":"Research and development of therapeutic mAbs:An analysis based on pipeline projects","volume":"11","author":"Geng","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"150927","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An overview of monoclonal antibodies","volume":"35","author":"Bayer","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"996469","DOI":"10.3389\/fimmu.2022.996469","article-title":"Autoreactive lymphocytes in multiple sclerosis:Pathogenesis and treatment target","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis:Practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(05)00992-0","article-title":"The neuro-ophthalmology of multiple sclerosis","volume":"4","author":"Frohman","year":"2005","journal-title":"Lancet Neurol"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"102730","DOI":"10.1016\/j.msard.2020.102730","article-title":"Neuro-ophthalmologic manifestations of multiple sclerosis other than acute optic neuritis","volume":"48","author":"Costa Novo","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0074-7742(07)79028-1","article-title":"Optic neuritis and the neuro-ophthalmology of multiple sclerosis","volume":"79","author":"Kaur","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"a028928","DOI":"10.1101\/cshperspect.a028928","article-title":"Clinical course of multiple sclerosis","volume":"8","author":"Klineova","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13311-022-01224-9","article-title":"Monoclonal antibodies in the treatment of relapsing multiple sclerosis:An overview with emphasis on pregnancy, vaccination, and risk management","volume":"19","author":"Krajnc","year":"2022","journal-title":"Neurotherapeutics"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis:The 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3390\/v12060643","article-title":"Role of viruses in the pathogenesis of multiple sclerosis","volume":"12","author":"Tarlinton","year":"2020","journal-title":"Viruses"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41423-019-0221-5","article-title":"Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE","volume":"16","author":"Van Kaer","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1034\/j.1399-0039.2000.550205.x","article-title":"Multiple sclerosis:A modifying influence of HLA class I genes in an HLA class II associated autoimmune disease","volume":"55","author":"Fogdell-Hahn","year":"2000","journal-title":"Tissue Antigens"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment:From biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front Immunol"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier:From physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol Rev"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali","year":"2023","journal-title":"Front Neurol"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"Blymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-016-1653-y","article-title":"An updated histological classification system for multiple sclerosis lesions","volume":"133","author":"Kuhlmann","year":"2017","journal-title":"Acta Neuropathol"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/acn3.199","article-title":"Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis","volume":"2","author":"Salou","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"e61835","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3389\/fimmu.2015.00642","article-title":"B Cells are multifunctional players in multiple sclerosis pathogenesis:Insights from therapeutic interventions","volume":"6","author":"Claes","year":"2015","journal-title":"Front Immunol"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch Neurol"},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"R33-20240830","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells:A focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R34-20240830","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis:A review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","article-title":"Natalizumab:A new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"Hutchinson","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"R36-20240830","first-page":"1","article-title":"Natalizumab for relapsing remitting multiple sclerosis","volume":"1","author":"Pucci","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R37-20240830","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"Arandomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"R38-20240830","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis:Interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R39-20240830","first-page":"CD013247","article-title":"Ocrelizumab for multiple sclerosis","volume":"5","author":"Lin","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R41-20240830","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"R42-20240830","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cells8020090","article-title":"Aquaporin-4 water channel in the brain and its implication for health and disease","volume":"8","author":"Mader","year":"2019","journal-title":"Cells"},{"key":"R43-20240830","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"R44-20240830","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R45-20240830","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica:A review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler"},{"key":"R46-20240830","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"R47-20240830","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0042-1743211","article-title":"Longitudinally extensive transverse myelitis:One disease, variable outcomes-a case series","volume":"13","author":"Chandrasekar","year":"2022","journal-title":"J Neurosci Rural Pract"},{"key":"R48-20240830","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/BOR.0000000000000603","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"31","author":"Romeo","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R49-20240830","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome:Frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"key":"R50-20240830","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneurol.2009.264","article-title":"Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis:New neurochemical and immunological implications","volume":"66","author":"Kanbayashi","year":"2009","journal-title":"Arch Neurol"},{"key":"R51-20240830","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/archneurol.2012.300","article-title":"Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody:A case report and literature review","volume":"69","author":"Suzuki","year":"2012","journal-title":"Arch Neurol"},{"key":"R52-20240830","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"R53-20240830","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","article-title":"Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution","volume":"80","author":"Matthews","year":"2013","journal-title":"Neurology"},{"key":"R54-20240830","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1073\/pnas.1119288109","article-title":"Illuminating neuromyelitis optica pathogenesis","volume":"109","author":"Ransohoff","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R55-20240830","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica:A systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"R56-20240830","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1177\/1352458514537699","article-title":"An epidemiological study of neuromyelitis optica in Isfahan","volume":"20","author":"Etemadifar","year":"2014","journal-title":"Mult Scler"},{"key":"R57-20240830","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J Neurol"},{"key":"R58-20240830","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s12264-020-00525-3","article-title":"Monoclonal antibody-based treatments for neuromyelitis optica spectrum disorders:From bench to bedside","volume":"36","author":"Zhu","year":"2020","journal-title":"Neurosci Bull"},{"key":"R59-20240830","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"R60-20240830","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1177\/1352458513498125","article-title":"Neuromyelitis optica and pregnancy during therapeutic B cell depletion:Infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum","volume":"19","author":"Ringelstein","year":"2013","journal-title":"Mult Scler"},{"key":"R61-20240830","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R62-20240830","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","article-title":"Pathology of demyelinating diseases","volume":"7","author":"Popescu","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"R63-20240830","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"R64-20240830","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"Aserum autoantibody marker of neuromyelitis optica:Distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"R65-20240830","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R66-20240830","first-page":"4025","article-title":"Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"R67-20240830","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/1352458510380416","article-title":"Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population","volume":"16","author":"Vaknin-Dembinsky","year":"2010","journal-title":"Mult Scler"},{"key":"R68-20240830","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders:From pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"key":"R69-20240830","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat Med"},{"key":"R70-20240830","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"Arole for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"R71-20240830","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy:Lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"key":"R72-20240830","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder:A randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"R73-20240830","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","article-title":"Satralizumab:First approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"R74-20240830","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40263-023-00995-9","article-title":"Satralizumab:A review in neuromyelitis optica spectrum disorder","volume":"37","author":"Fung","year":"2023","journal-title":"CNS Drugs"},{"key":"R75-20240830","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"R76-20240830","doi-asserted-by":"crossref","first-page":"104025","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R77-20240830","doi-asserted-by":"crossref","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD):A review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"R78-20240830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yebeh.2015.10.032","article-title":"Exploring the efficacy of a 5-day course of transcranial direct current stimulation (TDCS) on depression and memory function in patients with well-controlled temporal lobe epilepsy","volume":"55","author":"Liu","year":"2016","journal-title":"Epilepsy Behav"},{"key":"R79-20240830","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med"},{"key":"R80-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J Neurochem"},{"key":"R81-20240830","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"key":"R82-20240830","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R83-20240830","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"R84-20240830","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"R86-20240830","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease:International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"R87-20240830","doi-asserted-by":"crossref","first-page":"103356","DOI":"10.1016\/j.msard.2021.103356","article-title":"AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"57","author":"Marignier","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R88-20240830","doi-asserted-by":"crossref","first-page":"13368","DOI":"10.3390\/ijms241713368","article-title":"Pathogenesis, clinical features, and treatment of patients with myelin oligodendrocyte glycoprotein (MOG) autoantibody-associated disorders focusing on optic neuritis with consideration of autoantibody-binding sites:A review","volume":"24","author":"Tanaka","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R89-20240830","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+neurological disease is similar to AQP4-IgG+NMOSD but distinct from MS:A cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R90-20240830","doi-asserted-by":"crossref","first-page":"e055392","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease:A cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"key":"R91-20240830","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"R92-20240830","doi-asserted-by":"crossref","first-page":"102696","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD):A case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R93-20240830","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00005792-199909000-00002","article-title":"Systemic vasculitis in adults in Northwestern Spain, 1988-1997. Clinical and epidemiologic aspects","volume":"78","author":"Gonz\u00e1lez-Gay","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"R94-20240830","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/ard.2009.111005","article-title":"Increase in age at onset of giant cell arteritis:A population-based study","volume":"69","author":"Kermani","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R95-20240830","doi-asserted-by":"crossref","first-page":"103413","DOI":"10.1016\/j.autrev.2023.103413","article-title":"Performance of the new 2022 ACR\/EULAR classification criteria for giant cell arteritis in clinical practice in relation to its clinical phenotypes","volume":"22","author":"Narv\u00e1ez","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R96-20240830","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/PAS.0000000000000244","article-title":"Inflamed temporal artery:Histologic findings in 354 biopsies, with clinical correlations","volume":"38","author":"Cavazza","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R97-20240830","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199711063371902","article-title":"Color duplex ultrasonography in the diagnosis of temporal arteritis","volume":"337","author":"Schmidt","year":"1997","journal-title":"N Engl J Med"},{"key":"R98-20240830","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41433-023-02433-y","article-title":"Giant cell arteritis:Reviewing the advancing diagnostics and management","volume":"37","author":"Bilton","year":"2023","journal-title":"Eye (Lond)"},{"key":"R99-20240830","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0161-6420(93)31608-8","article-title":"Visual prognosis in giant cell arteritis","volume":"100","author":"Aiello","year":"1993","journal-title":"Ophthalmology"},{"key":"R100-20240830","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0161-6420(03)00228-8","article-title":"Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy","volume":"110","author":"Hayreh","year":"2003","journal-title":"Ophthalmology"},{"key":"R102-20240830","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R103-20240830","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"R104-20240830","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis:A phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"R106-20240830","first-page":"CD013484","article-title":"Tocilizumab for giant cell arteritis","volume":"5","author":"Antonio","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R107-20240830","first-page":"e24954","article-title":"Graves'ophthalmopathy in the setting of primary hypothyroidism","volume":"14","author":"Alajmi","year":"2022","journal-title":"Cureus"},{"key":"R108-20240830","first-page":"168","article-title":"Management of graves'ophthalmopathy:Reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"R109-20240830","first-page":"1104","article-title":"Typical graves'ophthalmopathy in primary hypothyroidism","volume":"67","author":"Kiran","year":"2017","journal-title":"J Pak Med Assoc"},{"key":"R110-20240830","first-page":"1232","article-title":"The thyrotropin receptors spread themselves around","volume":"79","author":"Davies","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"R111-20240830","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1172\/JCI113672","article-title":"Thyroid-stimulating hormone and insulin-like growth factor-1 synergize to elevate 1,2-diacylglycerol in rat thyroid cells. Stimulation of DNA synthesis via interaction between lipid and adenylyl cyclase signal transduction systems","volume":"82","author":"Brenner-Gati","year":"1988","journal-title":"J Clin Invest"},{"key":"R112-20240830","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves'disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R113-20240830","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ncpendmet0497","article-title":"Management of graves'ophthalmopathy","volume":"3","author":"Wiersinga","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"R114-20240830","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","article-title":"Teprotumumab:A review in thyroid eye disease","volume":"82","author":"Nie","year":"2022","journal-title":"Drugs"},{"key":"R116-20240830","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4103\/0301-4738.145987","article-title":"Ocular myasthenia gravis:A review","volume":"62","author":"Nair","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"R117-20240830","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01215447","article-title":"Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects","volume":"84","author":"Sommer","year":"1993","journal-title":"Doc Ophthalmol"},{"key":"R118-20240830","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.293.15.1906","article-title":"Does this patient have myasthenia gravis?","volume":"293","author":"Scherer","year":"2005","journal-title":"JAMA"},{"key":"R119-20240830","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0161-6420(00)00465-6","article-title":"Effect of local heat versus ice on blepharoptosis resulting from ocular myasthenia","volume":"107","author":"Movaghar","year":"2000","journal-title":"Ophthalmology"},{"key":"R120-20240830","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0972-5229.148631","article-title":"Therapeutic plasma exchange in the treatment of myasthenia gravis","volume":"19","author":"Kumar","year":"2015","journal-title":"Indian J Crit Care Med"},{"key":"R121-20240830","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"R122-20240830","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis:The RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"R123-20240830","first-page":"1","article-title":"Rituximab for the Treatment of Myasthenia Gravis:A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines","author":"Banerjee","year":"2018","journal-title":"CADTH Rapid Response Report Summary with Critical Apprais"},{"key":"R124-20240830","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","article-title":"Current drug treatment of myasthenia gravis","volume":"36","author":"Vanoli","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"R125-20240830","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab:A review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"R126-20240830","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities:A collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"R127-20240830","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy:A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"R128-20240830","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced guillain-barr\u00e9syndrome revealed by an occlusive enteric neuropathy:A differential diagnosis for ipilimumab-induced colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J Immunother"},{"key":"R129-20240830","first-page":"1","article-title":"GQ1b Seropositive Guillain-Barr\u00e9\/Miller Fisher Overlap Syndrome After Pembrolizumab Treatment","volume":"0","author":"Hunt","year":"2023","journal-title":"J Neuroophthalmol"},{"key":"R130-20240830","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"R131-20240830","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1941874418778957","article-title":"Miller fisher syndrome associated with immunotherapy for metastatic melanoma","volume":"8","author":"Baird-Gunning","year":"2018","journal-title":"Neurohospitalist"},{"key":"R132-20240830","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WNO.0000000000000755","article-title":"GQ1b-seronegative miller fisher syndrome associated with pembrolizumab","volume":"39","author":"Green","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"R133-20240830","doi-asserted-by":"crossref","first-page":"e229443","DOI":"10.1136\/bcr-2019-229443","article-title":"A rare case of Miller Fisher variant of Guillain-Barr\u00e9Syndrome (GBS) induced by a checkpoint inhibitor","volume":"12","author":"McNeill","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R134-20240830","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.neuron.2023.05.022","article-title":"PD-L1\/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior","volume":"111","author":"Zhao","year":"2023","journal-title":"Neuron"},{"key":"R135-20240830","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R136-20240830","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"key":"R137-20240830","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing Immune Checkpoint-Blocking Antibody Side Effects","volume":"1","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"R138-20240830","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","article-title":"Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma:A new cause of uveitis","volume":"27","author":"Robinson","year":"2004","journal-title":"J Immunother"},{"key":"R139-20240830","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R140-20240830","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s13760-021-01623-3","article-title":"Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab","volume":"121","author":"Nakamagoe","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"R141-20240830","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19:A randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"R142-20240830","first-page":"233","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antib Ther"}],"container-title":["Saudi Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_256_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:29:10Z","timestamp":1787768950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_256_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/sjopt.sjopt_256_23","relation":{},"ISSN":["1319-4534","2542-6680"],"issn-type":[{"value":"1319-4534","type":"print"},{"value":"2542-6680","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-10-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}